We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Targeting S-Nitrosylated PKM2: A Novel Therapeutic Frontier in Cardiac Fibrosis and Mitochondrial Dynamics

MedXY Editorial Team•Mar 3, 2026•Cardiology
mitapivatPKM2

Highlights

  • S-nitrosylation (SNO) of Pyruvate Kinase Isoform 2 (PKM2) at Cys49 and Cys326 is a specific hallmark of activated cardiac fibroblasts in heart failure.
  • SNO-PKM2 disrupts PKM2 tetramerization and reduces enzyme activity, shifting the metabolic and structural state of the cell.
  • Mechanistically, SNO-PKM2 promotes excessive mitochondrial fission by interfering with the actin regulatory protein gelsolin, leading to mitochondrial dysfunction and fibroblast activation.
  • The FDA-approved drug mitapivat and the activator TEPP-46 effectively reverse these pathways, presenting a viable therapeutic strategy for mitigating cardiac fibrosis.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

GLI1 Activation in Intermittent Hypoxia: A Novel Mechanistic Link Driving Cardiac Fibrosis in Obstructive Sleep ApneaThis study reveals that intermittent hypoxia activates GLI1 transcription factor in cardiac fibroblasts, driving fibrosis via PKM2-mediated glycolysis, and highlights GLI1 as a promising therapeutic target in OSA-associated cardiac dysfunctAug 25, 2026Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE TrialMitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.Oct 1, 2025
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story